Risankizumab
FDA Approves Risankizumab for Ulcerative Colitis
The FDA has approved risankizumab (Skyrizi, AbbVie) for patients with moderate to severe ulcerative colitis.
JUNE 27, 2024

Anti–IL-23 Agents Effective After Prior UC Treatment Failure
VANCOUVER, B.C.—Two different monoclonal antibodies targeting the interleukin-23 p19 subunit achieved all of ...
JANUARY 26, 2024

More Insight Into Anti-Interleukins
This month’s report focuses on the anti-interleukin treatments for inflammatory bowel disease, specifically ...
SEPTEMBER 21, 2023

FDA Grants Second Indication for Skyrizi
Risankizumab-rzaa is an interleukin-23 (IL-23) inhibitor that selectively blocks IL-23 by binding to its p19 ...
JANUARY 24, 2022

Extended Risankizumab Induction Needed for Some Patients
Some Crohn’s disease patients may require 24 weeks before experiencing a response to treatment with ...
JANUARY 5, 2022
